While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > BUSINESS
BUSINESS
- Ono to Conduct Joint Research with German Pharmaceutical Company Using Affilin Technology
May 18, 2012
- Ishibashi to Become SSP President, Torii to Be Withdrawn from Presidency
May 18, 2012
- Morishita Jintan, AnGes MG Jointly Research and Develop Oral Vaccine
May 18, 2012
- Pfizer Resubmit NDA for Fesoterodine Fumarate in March
May 18, 2012
- Eisai Sets Domestic Sales Forecast for Aricept at 90 Billion Yen on Impact of Generics
May 17, 2012
- Double-Digit Drop in Sales, Profits Reported Due to Patent Expiration of Aricept: Eisai
May 17, 2012
- Nichi-Iko, sanofi-aventis to Copromote Lipitor Generic Aiming at Cumulative Sales of 10 Billion Yen over 5 Years
May 17, 2012
- Sawai Targets Sales of 100 Billion Yen in FY2014, Gives Up Biosimilars Development: New Midterm Plan
May 17, 2012
- FY2011 Settlement of Accounts: Second-Tier Drug Makers Struggled, Domestic-Focused Mid-Sized Makers Posted Growth
May 17, 2012
- Top Five Drug Makers Report 12.8% Decline in Operating Profits with 3 Reporting Double-Digit Falls in Profits
May 17, 2012
- Final Costs to Be Confirmed by Product, Changing from Manufacturer Basis: Medipal Group
May 16, 2012
- Pivotal Focus for Biosimilars Business on Japan: Daiichi Sankyo President Nakayama
May 16, 2012
- Vedolizumab Achieved Remission in Crohn’s Disease Patients in PIII: Takeda
May 16, 2012
- Eisai to Increase the Number of Representative Corporate Officers from 2 to 5
May 16, 2012
- Ethical Drug Sales Down 0.2% in March, But Steady Despite Negative Factors: Crecon Report
May 16, 2012
- Short-Acting General Anesthetic ONO-2745/CNS 7056 Achieves Loss of Consciousness in All Patients: Ono
May 16, 2012
- Santen to Establish Presence in Market for Back-of-the-Eye Area with VEGF Trap-Eye
May 16, 2012
- Operating Profit Ratio for Pharmaceutical Wholesales at 0.32%, Improved but Still in Low Range: Top 4 Wholesalers
May 15, 2012
- Midterm Plan to Overcome Generic Versions of Actos, Setting Sights on Emerging Markets: Takeda
May 15, 2012
- Astellas to File for MDV3100 by June in Europe and US
May 15, 2012
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…